BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

ADMA Biologics (ADMA)ADMA BiologicsEarnings

Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and

Open original release

Related news

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-02-18 12:00 EST

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

CHRSCoherus BioSciences, Inc.2026-05-04 13:30 EST

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

RXRXRecursion2026-04-29 11:59 EST

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

MDXGMiMedx2026-04-29 20:01 EST

MIMEDX Announces First Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-04-22 12:00 EST

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

RXRXRecursion2026-02-18 13:30 EST

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

IBIOIbio Inc2026-05-12 20:05 EST

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

IBIOIbio Inc2026-02-10 21:05 EST

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

View all latest news

ADMA Biologics

ADMA Biologics is a plasma-derived biologics company focused on immunoglobulin therapies and specialty immune products. Its business is centered on plasma supply, manufacturing, and commercial execution.

Recent company news

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

ADMAADMA Biologics2026-03-27 11:00 EST

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

ADMAADMA Biologics2026-03-25 10:30 EST

ADMA Biologics Addresses Misleading Short-Seller Report

Stock data

Close
8.48 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States